Overview
MIMETAS is a global leader in human disease modeling, providing organ-on-a-chip platforms that enable pharmaceutical companies to conduct drug discovery and toxicity testing using physiologically relevant 3D tissue models. Their OrganoPlate technology supports up to 96 tissue models per plate with membrane-free extracellular matrix formation, while their OrganoPlate UniFlow system enables unidirectional, gravity-driven flow for large-scale screening without external pumps. The company offers pre-built models for liver, lung, brain, vasculature, and tumor tissues, as well as custom service offerings for immunological, cardiovascular, metabolic, and cancer research.
Frequently asked questions
- What is the OrganoPlate and how does it differ from traditional organ-on-chip systems?
- The OrganoPlate is a microfluidics-based platform that supports up to 96 tissue models on a single plate. Unlike conventional organs-on-chips, it features patented liquid handling technology that enables membrane-free formation of extracellular matrices in 3D, allowing free movement and interactions of cells with the introduction of proteins and co-culture compounds.
- What organ models does MIMETAS currently offer?
- MIMETAS offers advanced 3D human organ-on-chip models including liver, lung, brain, vasculature, and tumor tissues. Their blood-brain barrier model, published in February 2026, features self-assembling human tissue composed of primary brain microvascular endothelial cells, pericytes, and astrocytes that remain viable for at least 14 days.
- Can MIMETAS platforms assess drug efficacy and toxicity?
- Yes. MIMETAS has demonstrated that their OrganoPlate combined with high-content imaging systems can be used for assessing neurological drug efficacy and toxicity. The platform's physiologically accurate tissue models enable rigorous scientific studies and large-scale screening for drug discovery applications.
- What is OrganoPlate UniFlow and what are its advantages?
- OrganoPlate UniFlow is a unidirectional, gravity-driven pumpless flow system launched in January 2025 that supports up to 512 chips in a single setup. It eliminates the need for external pumps, simplifying operation while enhancing model accuracy and enabling physiologically accurate tissue models that replicate natural biological conditions.
- Does MIMETAS offer services in addition to products?
- Yes. MIMETAS provides comprehensive service offerings that guide pharmaceutical clients through every phase of drug discovery using their organ-on-chip technology. Their services include pre-built organ models and custom research support for disease modeling and drug development.